DAVENPORT 13F: Cuts Enovis (ENOV) Stake by $42M

Inside Davenport's Enovis Trade

Davenport significantly scaled back its investment in Enovis Corporation NYSE:ENOV, according to a Form 13F filing disclosed on October 14, 2026. The fund slashed its position by a dramatic 99.1%, unloading 2,319,531 shares during the quarter. That left the firm holding just 21,990 shares, with a reported market value of $401,757 at the time. Keep in mind that 13F filings are backward-looking and reflect portfolio snapshots from the end of the reporting period, meaning they may not represent the fund's exact current stance today.

Other Institutional Activity in Enovis

Other large money managers adjusted their positions in Enovis around the same time. Blackrock Inc. grew its holdings by 358,724 shares, ending with 10,295,666 shares worth about $201,692,098. American Century Companies Inc lifted its stake by 28.1%, adding 1,337,673 shares to reach 6,106,561 shares valued at $119,627,530. Vanguard Portfolio Management LLC grew its holdings by 117,685 shares, ending with 3,926,268 shares worth about $76,915,590. Rubric Capital Management LP boosted its stake by 59.0%, picking up 1,446,707 shares to finish with 3,900,000 shares valued at $76,401,000. Meanwhile, Vanguard Capital Management LLC trimmed its stake by 2.7%, shedding 68,151 shares to hold 2,484,318 shares worth roughly $48,667,789.

Enovis Corporation Stock Up 0.9%

Enovis shares recently traded around $19.53 as of October 16, 2026. The stock has faced downward pressure, trading roughly 7.1% below its 50-day moving average of $21.01 and about 16.6% below its 200-day moving average of $23.41. The shares sit 43.0% below their 52-week high of $34.28 while remaining 16.9% above their 52-week low of $16.70.

Recent Earnings

Enovis reported $2.30 billion in trailing twelve-month revenue. The medical technology company posted a negative trailing earnings per share of $19.23, alongside a net profit margin of negative 48.0% and a return on equity of negative 54.1%. The company's next quarterly financial update is scheduled for November 5, 2026.

Insider Buying and Selling at Enovis Corporation

Company insiders were active in the open market ahead of the filing. On June 15, 2026, Chief Administrative Officer Oliver Engert bought 1,000 shares at a price of $20.92 per share for a total value of $20,920. Engert later picked up another 7,598 shares valued at $149,971 on September 3, 2026. Chief Executive Officer Damien Mcdonald bought 13,035 shares at $19.15 apiece on September 4, 2026, totaling $249,620. On the same day, Oliver Engert bought an additional 2,660 shares at $18.80 each, worth $50,008.

Analysts Set New Price Targets

Analyst firms covering Enovis adjusted their expectations through late summer and early fall. On September 1, 2026, BTIG maintained its Buy rating while lowering its price target from $40.00 to $36.00. Wells Fargo maintained an Overweight rating on September 2, 2026, cutting its target from $39.00 to $33.00. Citizens maintained a Market Outperform rating on September 2, 2026, trimming its target from $55.00 to $47.00. Freedom Capital Markets maintained a Buy rating on September 2, 2026, adjusting its target from $41.00 to $36.00. Needham maintained a Buy rating on October 12, 2026, lowering its target from $52.00 to $34.00. Overall, the stock holds a consensus strong buy rating with a mean target price of $36.08 across 12 analyst opinions.

About Enovis

Enovis Corporation operates as a medical technology company focused on creating clinically differentiated healthcare solutions. Headquartered in Lewisville, Texas, the firm serves domestic and international markets through two primary segments: Prevention and Recovery, and Reconstructive devices.

Bottom Line

Investors will look toward Enovis's upcoming earnings release on November 5, 2026, for fresh insights into the company's financial turnaround. Because institutional filings like Davenport's report on past quarters, tracking subsequent disclosures will reveal whether other funds followed suit or chose to accumulate shares.